<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37908849</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Distinct temporal trajectories and risk factors for Post-acute sequelae of SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>1227883</StartPage><MedlinePgn>1227883</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1227883</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2023.1227883</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The understanding of Post-acute sequelae of SARS-CoV-2 infection (PASC) can be improved by longitudinal assessment of symptoms encompassing the acute illness period. To gain insight into the various disease trajectories of PASC, we assessed symptom evolution and clinical factors associated with the development of PASC over 3 months, starting with the acute illness period.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a prospective cohort study to identify parameters associated with PASC. We performed cluster and case control analyses of clinical data, including symptomatology collected over 3 months following infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We identified three phenotypic clusters associated with PASC that could be characterized as remittent, persistent, or incident based on the 3-month change in symptom number compared to study entry: remittent (median; min, max: -4; -17, 3), persistent (-2; -14, 7), or incident (4.5; -5, 17) (<i>p</i> = 0.041 remittent vs. persistent, <i>p</i> &lt; 0.001 remittent vs. incident, <i>p</i> &lt; 0.001 persistent vs. incident). Despite younger age and lower hospitalization rates, the incident phenotype had a greater number of symptoms (15; 8, 24) and a higher proportion of participants with PASC (63.2%) than the persistent (6; 2, 9 and 52.2%) or remittent clusters (1; 0, 6 and 18.7%). Systemic corticosteroid administration during acute infection was also associated with PASC at 3 months [OR (95% CI): 2.23 (1.14, 4.36)].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">An incident disease phenotype characterized by symptoms that were absent during acute illness and the observed association with high dose steroids during acute illness have potential critical implications for preventing PASC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Chen, Parthasarathy, Leung, Wu, Drake, Ridaura, Zisser, Conrad, Tapson, Moy, deFilippi, Rosas, Prabhakar, Basit, Salvatore, Krishnan and Kim.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Parthasarathy</LastName><ForeName>Sairam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Arizona, Tucson, AZ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Jacqueline M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Michelle J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drake</LastName><ForeName>Katherine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ridaura</LastName><ForeName>Vanessa K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zisser</LastName><ForeName>Howard C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conrad</LastName><ForeName>William A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Providence Little Company of Mary Medical Center Torrance, Torrance, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tapson</LastName><ForeName>Victor F</ForeName><Initials>VF</Initials><AffiliationInfo><Affiliation>Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moy</LastName><ForeName>James N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Rush University Medical Center, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>deFilippi</LastName><ForeName>Christopher R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Inova Heart and Vascular Institute, Falls Church, VA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosas</LastName><ForeName>Ivan O</ForeName><Initials>IO</Initials><AffiliationInfo><Affiliation>Department of Medicine, Baylor College of Medicine, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabhakar</LastName><ForeName>Bellur S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basit</LastName><ForeName>Mujeeb</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvatore</LastName><ForeName>Mirella</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>Jerry A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Breathe Chicago Center, University of Illinois Chicago, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Charles C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Verily Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002384</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">symptom clusters</Keyword></KeywordList><CoiStatement>CC, JL, MW, KD, and CK maintain equity ownership and employment at Verily Life Sciences. SP reports personal fees from Jazz Pharmaceuticals, Inc., and UpToDate, Inc., and grants from Philips, Inc., Sommetrics, Inc., and Regeneron. CRd serves on advisory boards for Abbott Diagnostics, Ortho/Quidel Diagnostics, and Roche Diagnostics. JK receives research funding from Regeneron. JK has also provided consulting for GlaxoSmithKline, AstraZeneca, CereVu Medical, Propeller/ResMed, and BData, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer RP declared a past co-authorship with the author SP to the handling editor.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>1</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37908849</ArticleId><ArticleId IdType="pmc">PMC10614284</ArticleId><ArticleId IdType="doi">10.3389/fmed.2023.1227883</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bull-Otterson L. Post&#x2013;COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 Years&#x2013;United States, March 2020&#x2013;November 2021. MMWR Morb Mortal Wkly Rep. (2022) 71:713&#x2013;7. 10.15585/mmwr.mm7121e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7121e1</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun. (2021) 12:6571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. (2022) 375:1122&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. (2022) 43:268&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID.
Department of Health and Human Services, Office of the Assistant Secretary for Health. National Research Action Plan on Long COVID. (2022). Available online at: https://www.covid.gov/assets/files/National-Research-Action-Plan-on-Long-COVID-08012022.pdf (accessed November 11, 2022).</Citation></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. (2022) 400:452&#x2013;61. 10.1016/S0140-6736(22)01214-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. (2023) 29:2347&#x2013;57. 10.1038/s41591-023-02521-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02521-2</ArticleId><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO R&amp;D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis. Geneva: WHO; (2022).</Citation></Reference><Reference><Citation>Recovery Collaborative Group Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. (2021) 384:693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - Final report. N Engl J Med. (2020) 383:1813&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo GD, Lazarini F, Levallois S, Hautefort C, Michel V, Larrous F, et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med. (2021) 13:eabf8396. 10.1126/scitranslmed.abf8396</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf8396</ArticleId><ArticleId IdType="pmc">PMC8158965</ArticleId><ArticleId IdType="pubmed">33941622</ArticleId></ArticleIdList></Reference><Reference><Citation>James LM, Georgopoulos AP. At the root of 3 &#x201c;Long&#x201d; diseases: persistent antigens inflicting chronic damage on the brain and other organs in gulf war illness, Long-COVID-19, and chronic fatigue syndrome. Neurosci Insights. (2022) 17:26331055221114817. 10.1177/26331055221114817</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/26331055221114817</ArticleId><ArticleId IdType="pmc">PMC9335483</ArticleId><ArticleId IdType="pubmed">35910083</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Lee KA, Lochlainn MN, Varsavsky T, Murray B, Graham MS, et al. Symptom clusters in COVID-19: a potential clinical prediction tool from the COVID symptom study app. Sci Adv. (2021) 7:eabd4177. 10.1126/sciadv.abd4177</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd4177</ArticleId><ArticleId IdType="pmc">PMC7978420</ArticleId><ArticleId IdType="pubmed">33741586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G, McCann K, O&#x2019;Brien C, Savinelli S, Tinago W, Yousif O, et al. Identification of distinct long COVID clinical phenotypes through cluster analysis of self-reported symptoms. Open Forum Infect Dis. (2022) 9:ofac060. 10.1093/ofid/ofac060</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac060</ArticleId><ArticleId IdType="pmc">PMC8900926</ArticleId><ArticleId IdType="pubmed">35265728</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Thorpe LE, Simon NM, de Havenon A, Yaghi S, Sabadia SB, et al. Post-acute sequelae of COVID-19 symptom phenotypes and therapeutic strategies: a prospective, observational study. PLoS One. (2022) 17:e0275274. 10.1371/journal.pone.0275274</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0275274</ArticleId><ArticleId IdType="pmc">PMC9521913</ArticleId><ArticleId IdType="pubmed">36174032</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. (2021) 27:601&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zang C, Xu Z, Zhang Y, Xu J, Bian J, et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med. (2023) 29:226&#x2013;35. 10.1038/s41591-022-02116-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02116-3</ArticleId><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. (2022) 185:881&#x2013;95.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb M, Wang R, Yu H, Spatz ES, Montoy JC, Rodriguez R, et al. Severe fatigue and persistent symptoms at three months following SARS-CoV-2 infections during the pre-delta, delta, and omicron time periods: a multicenter prospective cohort study. Clin Infect Dis. (2023) 76:1930&#x2013;41. 10.1093/cid/ciad045</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad045</ArticleId><ArticleId IdType="pmc">PMC10249989</ArticleId><ArticleId IdType="pubmed">36705268</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. (2022) 226:1593&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q, Zheng B, Daines L, Sheikh A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. (2022) 11:269. 10.3390/pathogens11020269</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. (2021) 4:e2128568. 10.1001/jamanetworkopen.2021.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Simon NM. Bridging knowledge gaps in the diagnosis and management of neuropsychiatric sequelae of COVID-19. JAMA Psychiatry. (2022) 79:811&#x2013;7. 10.1001/jamapsychiatry.2022.1616</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2022.1616</ArticleId><ArticleId IdType="pubmed">35767287</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. (2021) 4:e2111417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. (2021) 36:109518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;vik S, Barrat-Due A, K&#xe5;sine T, Olasveengen T, Strand MW, Tveita AA, et al. Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation. J Infect. (2022) 85:57&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9122884</ArticleId><ArticleId IdType="pubmed">35605805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulter HN, Licht JH, Bonner EL, Jr., Glynn RD, Sebastian A. Effects of glucocorticoid steroids on renal and systemic acid-base metabolism. Am J Physiol. (1980) 239:F30&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">7395993</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, et al. Distinguishing features of Long COVID identified through immune profiling. medRxiv [Preprint]. (2022). 10.1101/2022.08.09.22278592</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Rensen N, Gemke RJ, van Dalen EC, Rotteveel J, Kaspers GJ. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. Cochrane Database Syst Rev. (2017) 11:CD008727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6486149</ArticleId><ArticleId IdType="pubmed">29106702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>